Save information for later
Sign Up

Learn About Spastic Paraplegia Type 3A

What is the definition of Spastic Paraplegia Type 3A?

Spastic paraplegia type 3A is one of a group of genetic disorders known as hereditary spastic paraplegias. These disorders are characterized by muscle stiffness (spasticity) and weakness in the lower limbs (paraplegia). Hereditary spastic paraplegias are often divided into two types: pure and complex. The pure types involve only the lower limbs, while the complex types also involve other areas of the body; additional features can include changes in vision, changes in intellectual functioning, difficulty walking, and disturbances in nerve function (neuropathy). Spastic paraplegia type 3A is usually a pure hereditary spastic paraplegia, although a few complex cases have been reported.

What are the causes of Spastic Paraplegia Type 3A?

Mutations in the ATL1 gene cause spastic paraplegia type 3A. The ATL1 gene provides instructions for producing a protein called atlastin-1. Atlastin-1 is produced primarily in the brain and spinal cord (central nervous system), particularly in nerve cells (neurons) that extend down the spinal cord (corticospinal tracts). These neurons send electrical signals that lead to voluntary muscle movement. Atlastin-1 is involved in the growth of specialized extensions of neurons, called axons, which transmit nerve impulses that signal muscle movement. The protein also likely plays a role in the normal functioning of multiple structures within neurons and in distributing materials within these cells.

How prevalent is Spastic Paraplegia Type 3A?

Spastic paraplegia type 3A belongs to a subgroup of hereditary spastic paraplegias known as autosomal dominant hereditary spastic paraplegia, which has an estimated prevalence of 2 to 9 per 100,000 individuals. Spastic paraplegia type 3A accounts for 10 to 15 percent of all autosomal dominant hereditary spastic paraplegia cases.

Is Spastic Paraplegia Type 3A an inherited disorder?

Spastic paraplegia type 3A is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder. In approximately 95 percent of cases, an affected person inherits the mutation from one affected parent.

Who are the top Spastic Paraplegia Type 3A Local Doctors?

Florida Hospital Medical Group Inc

201 N Park Ave, Suite 301, 
Apopka, FL 
 (54.6 mi)
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Nivedita Jerath is a Neurologist in Apopka, Florida. Dr. Jerath and is rated as an Experienced provider by MediFind in the treatment of Spastic Paraplegia Type 3A. Her top areas of expertise are Charcot-Marie-Tooth Disease, Sensorimotor Polyneuropathy, Andersen-Tawil Syndrome, Rhizotomy, and Microvascular Decompression. Dr. Jerath is currently accepting new patients.

Villages Regional Hospital Physician Services LLC

10435 Se 170th Pl, 
Summerfield, FL 
 (24.4 mi)
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Robert Maiello is a Physiatrist in Summerfield, Florida. Dr. Maiello and is rated as an Experienced provider by MediFind in the treatment of Spastic Paraplegia Type 3A. His top areas of expertise are Hemiplegia, Miller-Fisher Syndrome, Guillain-Barre Syndrome, Vertebroplasty, and Bone Graft. Dr. Maiello is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More

Rehabilitation And Electrodiagnostics PA

625 E. Twiggs Street,, Suite 103, 
Tampa, FL 
 (65.6 mi)
Languages Spoken:
English, Filipino, Spanish
Accepting New Patients

Venerando Batas is a Physiatrist in Tampa, Florida. Dr. Batas and is rated as an Experienced provider by MediFind in the treatment of Spastic Paraplegia Type 3A. His top areas of expertise are Spasticity, Hemiplegia, Moebius Syndrome, and Cerebral Palsy. Dr. Batas is currently accepting new patients.

What are the latest Spastic Paraplegia Type 3A Clinical Trials?
Match to trials
Find the right clinical trials for you in under a minute
Get started
Who are the sources who wrote this article ?

Published Date: March 01, 2015
Published By: National Institutes of Health